Pacira CAO sells 13,137 shares under 10b5-1

Pacira BioSciences Chief Administrative Officer Kristen Williams reported two stock transactions.

Rhea-AI Filing Summary

Pacira BioSciences Chief Administrative Officer Kristen Williams reported two stock transactions. On January 30, 2026, 17,134 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at a price of $20.54 per share, leaving her with 144,440 shares held directly.

On February 2, 2026, she sold 13,137 Pacira common shares at $20.53 per share in a transaction carried out under a pre-established Rule 10b5-1 trading plan. After this sale, she directly held 131,303 Pacira shares.

Insider Trade Summary

Net Seller: 13,137 shares

Net Sell 2 txns

Insider WILLIAMS KRISTEN

Role Chief Administrative Officer

Sold 13,137 shs ($270K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,137	$20.53	$270K
Exercise Price or Tax Liability	Common Stock	17,134	$20.54	$352K

Holdings After Transaction: Common Stock — 131,303 shares (Direct)

Footnotes (2)

1. F1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
2. F2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Pacira (PCRX) report for Kristen Williams?

Pacira reported that Chief Administrative Officer Kristen Williams had 17,134 shares withheld for taxes on January 30, 2026, and sold 13,137 common shares on February 2, 2026, under a Rule 10b5-1 trading plan, with all holdings reported as directly owned.

How many Pacira (PCRX) shares did Kristen Williams sell and at what price?

Kristen Williams sold 13,137 Pacira common shares on February 2, 2026 at $20.53 per share. The transaction was coded as an open-market sale (code S) and executed under a previously adopted Rule 10b5-1 trading plan.

How many Pacira (PCRX) shares does Kristen Williams hold after the reported transactions?

After the February 2, 2026 sale, Kristen Williams directly held 131,303 Pacira common shares. Following the earlier January 30, 2026 tax-withholding transaction, her reported direct ownership was 144,440 shares, both figures reflecting post-transaction balances.

What was the purpose of the 17,134 Pacira (PCRX) shares withheld on January 30, 2026?

The 17,134 Pacira shares withheld on January 30, 2026 were used to cover tax withholding obligations arising from the vesting of a restricted stock unit award. These shares were retained by the issuer rather than sold on the open market.

Was Kristen Williams’ Pacira (PCRX) stock sale made under a Rule 10b5-1 plan?

Yes. The sale of 13,137 Pacira shares on February 2, 2026 was executed under a pre-established Rule 10b5-1 trading plan. Such plans allow insiders to schedule trades in advance, providing a structured framework for ongoing share dispositions.

What is Kristen Williams’ role at Pacira (PCRX) in this Form 4 filing?

In this Form 4, Kristen Williams is identified as an officer of Pacira BioSciences, serving as Chief Administrative Officer. She is not listed as a director or 10% owner, and all reported transactions involve Pacira common stock held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 06:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILLIAMS KRISTEN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		F		17,134(1)	D	$20.54	144,440	D
Common Stock	02/02/2026		S		13,137(2)	D	$20.53	131,303	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Remarks:

	/s/ Kristen Williams	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.